Beleodaq (belinostat) vs Velexbru (tirabrutinib hydrochloride)
Beleodaq (belinostat) vs Velexbru (tirabrutinib hydrochloride)
Beleodaq (belinostat) is a histone deacetylase inhibitor approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, a type of non-Hodgkin lymphoma. Velexbru (tirabrutinib hydrochloride), on the other hand, is a Bruton's tyrosine kinase (BTK) inhibitor used for treating conditions such as mantle cell lymphoma and Waldenström's macroglobulinemia, which are different types of non-Hodgkin lymphoma. The choice between Beleodaq and Velexbru would be based on the specific type of lymphoma a patient has, their overall health, previous treatments, and the mechanism of action of each drug, as they target different pathways in cancer cells.
Difference between Beleodaq and Velexbru
| Metric | Beleodaq (belinostat) | Velexbru (tirabrutinib hydrochloride) |
|---|---|---|
| Generic name | Belinostat | Tirabrutinib hydrochloride |
| Indications | Relapsed or refractory peripheral T-cell lymphoma | Relapsed or refractory B-cell malignancies |
| Mechanism of action | HDAC inhibitor | Bruton's tyrosine kinase (BTK) inhibitor |
| Brand names | Beleodaq | Velexbru |
| Administrative route | Intravenous | Oral |
| Side effects | Nausea, vomiting, fatigue, fever, etc. | Neutropenia, thrombocytopenia, diarrhea, etc. |
| Contraindications | Known hypersensitivity to belinostat or any component of the formulation | None specifically listed; use caution in patients with bleeding disorders or taking anticoagulants |
| Drug class | Antineoplastic agent, HDAC inhibitor | Antineoplastic agent, kinase inhibitor |
| Manufacturer | Spectrum Pharmaceuticals | Ono Pharmaceutical Co., Ltd. |
Efficacy
Beleodaq (Belinostat) for the Treatment of Lymphoma
Beleodaq (belinostat) is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a rare type of non-Hodgkin lymphoma that affects the T-cells of the immune system. The efficacy of Beleodaq in the treatment of PTCL was evaluated in a multicenter, single-arm clinical trial. In this study, Beleodaq demonstrated a 25.8% overall response rate with a median duration of response of 8.4 months, providing a significant therapeutic option for patients with this challenging condition.
While the results are promising, the effectiveness of Beleodaq for other types of lymphoma has not been established. Therefore, its use is specifically indicated for PTCL after the failure of at least one prior systemic therapy. The safety and efficacy of Beleodaq for the first-line treatment of PTCL or in combination with other chemotherapeutic agents have not been fully explored and require further clinical investigation.
Velexbru (Tirabrutinib Hydrochloride) for the Treatment of Lymphoma
Velexbru (tirabrutinib hydrochloride) is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in the treatment of B-cell malignancies, such as certain types of lymphoma. While it is not yet approved by the FDA, clinical trials have been conducted to assess its efficacy. In a phase II study involving patients with relapsed or refractory mantle cell lymphoma, Velexbru achieved an overall response rate of 67%, indicating a potential benefit for this patient population.
It is important to note that the use of Velexbru in the treatment of lymphoma is still under investigation, and its efficacy and safety profile continue to be evaluated in ongoing clinical trials. The results from these studies will provide further insight into the potential role of Velexbru in the management of lymphoma, including its use as a monotherapy or in combination with other therapeutic agents.
Regulatory Agency Approvals
Beleodaq
-
Food and Drug Administration (FDA), USA
Velexbru
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Beleodaq or Velexbru today
If Beleodaq or Velexbru are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us